Elanco Animal Health Incorporated Accounts Payable
Elanco Animal Health Incorporated (ELAN) had Accounts Payable of $427.00 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current › Accounts Payable and Accrued Liabilities, Current
us-gaap:AccountsPayableCurrent · last filed 2026-08-05
- 2026-06-30: Accounts Payable, Current $427.00M.
- 2026-03-31: Accounts Payable, Current $372.00M.
- 2025-12-31: Accounts Payable, Current $368.00M.
- 2025-09-30: Accounts Payable, Current $352.00M.
| Period end | Accounts Payable, Current | Accounts Payable, Current as first filed |
|---|---|---|
| 2026-06-30 | $427.00M 10-Q · filed 2026-08-05 | |
| 2026-03-31 | $372.00M 10-Q · filed 2026-05-06 | |
| 2025-12-31 | $368.00M 10-Q · filed 2026-08-05 | |
| 2025-09-30 | $352.00M 10-Q · filed 2025-11-05 | |
| 2025-06-30 | $368.00M 10-Q · filed 2025-08-07 | |
| 2025-03-31 | $330.00M 10-Q · filed 2025-05-07 | |
| 2024-12-31 | $296.00M 10-K · filed 2026-02-24 | |
| 2024-09-30 | $259.00M 10-Q · filed 2024-11-07 | |
| 2024-06-30 | $291.00M 10-Q · filed 2024-08-08 | |
| 2024-03-31 | $302.00M 10-Q · filed 2024-05-08 | |
| 2023-12-31 | $270.00M 10-K · filed 2025-02-25 | |
| 2023-09-30 | $296.00M 10-Q · filed 2023-11-07 | |
| 2023-06-30 | $354.00M 10-Q · filed 2023-08-07 | |
| 2023-03-31 | $381.00M 10-Q · filed 2023-05-09 | |
| 2022-12-31 | $390.00M 10-K · filed 2024-02-26 | |
| 2022-09-30 | $350.00M 10-Q · filed 2022-11-08 | |
| 2022-06-30 | $386.00M 10-Q · filed 2022-08-08 | |
| 2022-03-31 | $402.00M 10-Q · filed 2022-05-09 | |
| 2021-12-31 | $416.00M 10-K · filed 2023-03-01 | $418.00M 10-K · filed 2022-02-28 |
| 2021-09-30 | $436.00M 10-Q · filed 2021-11-05 | |
| 2021-06-30 | $506.00M 10-Q · filed 2021-08-09 | |
| 2021-03-31 | $411.00M 10-Q · filed 2021-05-07 | |
| 2020-12-31 | $501.00M 10-K · filed 2022-02-28 | |
| 2020-09-30 | $355.90M 10-Q · filed 2020-11-06 | |
| 2020-06-30 | $242.50M 10-Q · filed 2020-07-30 | |
| 2020-03-31 | $215.00M 10-Q · filed 2020-05-07 | |
| 2019-12-31 | $222.60M 10-K · filed 2021-03-01 | |
| 2019-09-30 | $206.10M 10-Q · filed 2019-11-08 | |
| 2019-06-30 | $242.90M 10-Q · filed 2019-08-13 | |
| 2019-03-31 | $252.10M 10-Q · filed 2019-05-14 | |
| 2018-12-31 | $205.20M 10-K · filed 2020-02-28 | |
| 2018-09-30 | $202.70M 10-Q · filed 2018-11-08 | |
| 2017-12-31 | $203.80M 10-K · filed 2019-02-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |